Department of Human Oncology, University of Wisconsin, Madison, WI 53706, USA.
Int Immunopharmacol. 2011 Nov;11(11):1877-86. doi: 10.1016/j.intimp.2011.07.019. Epub 2011 Aug 18.
We evaluated the anti-tumor effect of Resveratrol (RV) on M21 and NXS2 tumor cell lines and its immunosuppressive activity on human and murine immune cells to determine the potential for combining RV and immunotherapy. In vitro, concentrations of RV≥25 mcM, inhibited cell proliferation, blocked DNA synthesis and induced G1 phase arrest in tumor and immune cells. RV at 12-50 mcM inhibited antibody dependent cell mediated cytotoxicity (ADCC) of tumor cells facilitated by the hu14.18-IL2 immunocytokine (IC). The in vivo anti-tumor and immunomodulating activity of RV given systemically were assessed in mice. Results showed that this RV regimen inhibited the growth of NXS2 tumors in vivo but did not appear to interfere with blood cell count, splenocyte or macrophage function. Thus, RV may be a candidate for combining with immunotherapy.
我们评估了白藜芦醇(RV)对 M21 和 NXS2 肿瘤细胞系的抗肿瘤作用及其对人和鼠免疫细胞的免疫抑制活性,以确定 RV 与免疫疗法联合应用的潜力。在体外,浓度为≥25mcM 的 RV 抑制肿瘤和免疫细胞的细胞增殖,阻断 DNA 合成,并诱导 G1 期停滞。浓度为 12-50mcM 的 RV 抑制了由 hu14.18-IL2 免疫细胞因子(IC)介导的肿瘤细胞的抗体依赖的细胞介导的细胞毒性(ADCC)。系统给予 RV 的体内抗肿瘤和免疫调节活性在小鼠中进行了评估。结果表明,该 RV 方案抑制了 NXS2 肿瘤在体内的生长,但似乎不干扰血细胞计数、脾细胞或巨噬细胞功能。因此,RV 可能是与免疫疗法联合应用的候选药物。